Compare RCI & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCI | BIIB |
|---|---|---|
| Founded | 1960 | 1978 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | RCI | BIIB |
|---|---|---|
| Price | $37.58 | $181.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 23 |
| Target Price | $34.50 | ★ $176.48 |
| AVG Volume (30 Days) | 894.8K | ★ 1.9M |
| Earning Date | 10-23-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ 341.45 | N/A |
| EPS | 8.96 | ★ 10.97 |
| Revenue | ★ $15,091,643,989.00 | $10,065,900,000.00 |
| Revenue This Year | $7.45 | $3.61 |
| Revenue Next Year | $5.57 | N/A |
| P/E Ratio | ★ $4.18 | $16.52 |
| Revenue Growth | 2.75 | ★ 4.77 |
| 52 Week Low | $23.18 | $110.04 |
| 52 Week High | $40.26 | $185.17 |
| Indicator | RCI | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 72.92 |
| Support Level | $37.42 | $174.53 |
| Resistance Level | $39.25 | $182.94 |
| Average True Range (ATR) | 0.65 | 5.22 |
| MACD | -0.16 | 0.25 |
| Stochastic Oscillator | 8.47 | 83.54 |
Rogers Communications is the largest wireless service provider in Canada with more than 11 million subscribers, equating to one-third of the total Canadian market. Rogers' wireless business accounts for more than half of total revenue and has been growing at a higher rate than other segments. The cable segment, which provides about 38% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and the Toronto Blue Jays. Rogers' significant exposure to sports also includes ownership stakes in the Maple Leafs, Raptors, Toronto FC, and Argonauts.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).